Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Washington Hospital — Fremont, California
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in California: - Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente- Modesto MOB II — Modesto, California
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in California: - UCLA Hematology/Oncology - Alhambra — Alhambra, California
- UCLA Hematology/Oncology - Atascadero — Atascadero, California
- Cedars-Sinai Cancer Beverly Hills (drug treatment and dispensing location) — Beverly Hills, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- UCLA Hematology/Oncology - Beverly Hills — Beverly Hills, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in California: - UCLA Hematology/Oncology - Santa Monica ( Site 0044) — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center (0120) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Emad Ibrahim,MD,INC. ( Site 0012) — Redlands, California
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in California: - City of Hope Comprehensive Cancer Center ( Site 0049) — Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0059) — Irvine, California
- Moores Cancer Center ( Site 0010) — La Jolla, California
- Cedars-Sinai Medical Center ( Site 0068) — Los Angeles, California
- UCLA Hematology/Oncology - Santa Monica ( Site 0002) — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in California: - University of California at San Diego — La Jolla, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in California: - MemorialCare Orange Coast Medical Center — Fountain Valley, California
- University Of California San Diego — La Jolla, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Kaiser Permanente Southern California — Riverside, California
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in California: - Los Angeles Cancer Network (LACN) — Anaheim, California
- Los Angeles Cancer Network (LACN) — Fountain Valley, California
- Los Angeles Cancer Network (LACN) — Glendale, California
- Los Angeles Cancer Network (LACN) — Glendale, California
- Los Angeles Cancer Network (LACN) — Laguna Hills, California
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in California: - University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in California: - Research Site — La Jolla, California
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — San Diego, California
- Research Site — San Luis Obispo, California
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in California: - Urology Group of Southern California — Los Angeles, California
- Greater Los Angeles VA Medical Center — Los Angeles, California
- UC Irvine Health — Orange, California
- Stanford University Medical Center — Stanford, California
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in California: - Research Site — Irvine, California
- Research Site — Loma Linda, California
- Research Site — San Francisco, California
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in California: - VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
Phase 3 Recruiting Academic/Other
With people living longer after being treated for prostate cancer, quality of life has become a concern when considering the treatment plan. Sometimes after radiation therapy, patients may experience problems that affect the urinary and bo…
Sponsor: Jonsson Comprehensive Cancer Center
NCT ID: NCT07293585
Sites in California: - University of California at Los Angeles — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in California: - Site US10040 — Los Angeles, California
- Site US10009 — Los Angeles, California
- Site US10067 — Orange, California
- Site US10008 — San Bernardino, California
- Site US10042 — San Diego, California
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04071236
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in California: - VA Greater Los Angeles Healthcare System — Los Angeles, California
- UCLA Clark Urology Center — Los Angeles, California
- University of California San Francisco — San Francisco, California
Phase 2 Recruiting Industry
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Sponsor: Syncromune, Inc.
NCT ID: NCT06533644
Sites in California: - University of California-Davis — Sacramento, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in California: - MemorialCare Orange Coast Medical Center — Fountain Valley, California
- Cancer and Blood Research Center — Los Alamitos, California
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in California: - VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in California: - University of California, Davis Comprehensive Cancer Center — Sacramento, California
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California